Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Israel Biotech Fund
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 11, 2020
Proceeds support clinical advancement of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity.